Shandong Lukang reports 16.77% profit increase in Q1 2025

Shandong Lukang Pharmaceutical (SSE: 600789) announced a 16.77% increase in net profit attributable to shareholders for the first quarter of 2025, reaching CNY 78.6 million, compared to CNY 67.3 million in the same period last year. The company reported Q1 revenues of CNY 1.67 billion, a decrease of 6.95% compared to the CNY 1.80 billion reported in Q1 2024. Basic and diluted earnings per share both remained steady at CNY 0.09. Total assets edged up slightly to CNY 9.14 billion, while shareholders' equity increased 1.98% to CNY 3.99 billion. In other board matters, the company's recent board meeting held on April 29th approved the company's 2024 environmental, social, and governance report and confirmed their existing appointment of auditor, He Xin.